Mechanisms of cannabinoid tolerance
Biochemical Pharmacology · 2023-08 · 214 · 115665
DOI: 10.1016/j.bcp.2023.115665 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biochemical Pharmacology, 2023-08. Verfasst von Mary K Piscura und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Marshall University, Huntington, WV 25755, USA; Department of Biomedical Sciences, Edward Via College of Osteopath…. Hauptthemen laut MEDLINE: Cannabinoids. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 297 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS, National Institute on Drug Abuse, National Institutes of Health.
Abstract (Originalsprache)
Cannabis has been used recreationally and medically for centuries, yet research into understanding the mechanisms of its therapeutic effects has only recently garnered more attention. There is evidence to support the use of cannabinoids for the treatment of chronic pain, muscle spasticity, nausea and vomiting due to chemotherapy, improving weight gain in HIV-related cachexia, emesis, sleep disorders, managing symptoms in Tourette syndrome, and patient-reported muscle spasticity from multiple sclerosis. However, tolerance and the risk for cannabis use disorder are two significant disadvantages for cannabinoid-based therapies in humans. Recent work has revealed prominent sex differences in the acute response and tolerance to cannabinoids in both humans and animal models. This review will discuss evidence demonstrating cannabinoid tolerance in rodents, non-human primates, and humans and our current understanding of the neuroadaptations occurring at the cannabinoid type 1 receptor (CB1R) that are responsible tolerance. CB1R expression is downregulated in tolerant animals and humans while there is strong evidence of CB1R desensitization in cannabinoid tolerant rodent models. Throughout the review, critical knowledge gaps are indicated and discussed, such as the lack of a neuroimaging probe to assess CB1R desensitization in humans. The review discusses the intracellular signaling pathways that are responsible for mediating CB1R desensitization and downregulation including the action of G protein-coupled receptor kinases, β-arrestin2 recruitment, c-Jun N-terminal kinases, protein kinase A, and the intracellular trafficking of CB1R. Finally, the review discusses approaches to reduce cannabinoid tolerance in humans based on our current understanding of the neuroadaptations and mechanisms responsible for this process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Marshall University, Huntington, WV 25755, USA; Department of Biomedical Sciences, Edward Via College of Osteopathic Medicine, Auburn, AL 36832, USA.
- Department of Biomedical Sciences, Marshall University, Huntington, WV 25755, USA.
- Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.
- Department of Biomedical Sciences, Marshall University, Huntington, WV 25755, USA. Electronic address: morganda@marshall.edu.
Förderung
- NIDA NIH HHS
- National Institute on Drug Abuse
- National Institutes of Health
Zitieren
APA
Piscura, M. K., Henderson-Redmond, A. N., Barnes, R. C., Mitra, S., Guindon, J., & Morgan, D. J. (2023). Mechanisms of cannabinoid tolerance. Biochemical Pharmacology, 214, 115665. https://doi.org/10.1016/j.bcp.2023.115665
Vancouver
Piscura MK, Henderson-Redmond AN, Barnes RC, Mitra S, Guindon J, Morgan DJ. Mechanisms of cannabinoid tolerance. Biochemical Pharmacology. 2023;214:115665. doi:10.1016/j.bcp.2023.115665
BibTeX
@article{Piscura2023,
author = {Piscura, Mary K and Henderson-Redmond, Angela N and Barnes, Robert C and Mitra, Swarup and Guindon, Josée and Morgan, Daniel J},
title = {Mechanisms of cannabinoid tolerance},
journal = {Biochemical Pharmacology},
year = {2023},
volume = {214},
pages = {115665},
doi = {10.1016/j.bcp.2023.115665}
}
EUVIMED